Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help
 doctors detect early changes in the heart caused by chemotherapy.

 PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in
 patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.
OBJECTIVES:

 -  To determine whether early myocardial structural and functional changes can be detected
 using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin
 lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

 OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of
 doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of
 chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin
 lymphoma.
DISEASE CHARACTERISTICS:

 -  Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

 -  Newly diagnosed disease

 -  Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the
 University of Nebraska Medical Center

 PATIENT CHARACTERISTICS:

 -  Not pregnant or nursing

 -  Fertile patients must use effective contraception

 -  No pacemaker

 -  No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)

 -  Able to lie flat for 90 minutes

 -  No metallic foreign body not approved for MRI

 -  No known hypersensitivity to gadolinium contrast or other required drugs in the study

 -  No comorbidity or condition which, in the opinion of the investigator, may interfere
 with the assessments and procedures of this study

 -  Able to fulfill the requirements of the study

 PRIOR CONCURRENT THERAPY:

 -  See Disease Characteristics

 -  No prior chemotherapy

 -  No prior radiotherapy to mantle or mediastinum